Abstract
Despite advancements in health systems and intensive care unit (ICU) care, along with
the introduction of novel antibiotics and microbiologic techniques, mortality rates
in severe community-acquired pneumonia (sCAP) patients have not shown significant
improvement. Delayed admission to the ICU is a major risk factor for higher mortality.
Apart from choosing the appropriate site of care, prompt and appropriate antibiotic
therapy significantly affects the prognosis of sCAP. Treatment regimens involving
ceftaroline or ceftobiprole are currently considered the best options for managing
patients with sCAP. Additionally, several other molecules, such as delafloxacin, lefamulin,
and omadacycline, hold promise as therapeutic strategies for sCAP. This review aims
to provide a comprehensive summary of the key challenges in managing adults with severe
CAP, focusing on essential aspects related to antibiotic treatment and investigating
potential strategies to enhance clinical outcomes in sCAP patients.
Keywords
ceftobiprole - ceftaroline - sCAP - community-acquired pneumonia - ICU - new antibiotics
